Cocrystal Pharma, Inc. — Director's Dealing 2021

Jul 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2021-07-16

Reporting Person: Martin James Joseph (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-16	Stock Options (Right to Buy)	$1.11	A	250000	Acquired	2031-07-16	Common Stock (250000)	Direct

Footnotes

F1: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code").

F2: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 16, 2022 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to continued employment on each applicable vesting date.